Katelijn M. Blok

Katelijn M. Blok

Auto-generated profile, based on publicly available information

Katelijn M. Blok

Department of Neurology, MS Center ErasMS Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
LRLiza Rijvers
Liza Rijvers
JLJamie Van Langelaar
Jamie Van Langelaar
LBLaurens Bogers
Laurens Bogers
MMMarie-José Melief
Marie-José Melief
Steven C. KoetzierSteven C. Koetzier
Steven C. Koetzier
MLMarvin M. van Luijn
Marvin M. van Luijn
Recent clinical trials have shown promising results for the next-generation Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib in the treatment of multiple sclerosis (MS). BTK has a central role in signaling pathways that govern the development of B cells. Whether and how BTK activity shapes B cells as key drivers of MS is currently unclear. Compared with levels of BTK protein, we found higher levels of phospho-BTK in ex vivo blood memory B cells from patients with relapsing-remitting MS and secondary progressive MS compared with controls. In these MS groups, BTK activity was induced to a lesser extent after anti-IgM stimulation. BTK positively correlated with CXCR3 expression, both of which were increased in blood B cells from clinical responders to natalizumab (anti–VLA-4 antibody) treatment. Under in vitro T follicular helper–like conditions , BTK phosphorylation was enhanced by T-bet–inducing stimuli, IFN-γ and CpG-ODN, while the expression of T-bet and T-bet–associated molecules CXCR3, CD21, and CD11c was affected by evobrutinib. Furthermore, evobrutinib interfered with in vitro class switching, as well as memory recall responses, and disturbed CXCL10-mediated migration of CXCR3 + switched B cells through human brain endothelial monolayers. These findings demonstrate a functional link between BTK activity and disease-relevant B cells and offer valuable insights into how next-generation BTK inhibitors could modulate the clinical course of patients with MS.

1 November 2020 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
Steven C. KoetzierSteven C. Koetzier
Steven C. Koetzier
JLJamie van Langelaar
Jamie van Langelaar
KBKatelijn M. Blok
Katelijn M. Blok
TBThierry P.P. van Den Bosch
Thierry P.P. van Den Bosch
AWAnnet F. Wierenga-Wolf
Annet F. Wierenga-Wolf
MLMarvin M. van Luijn
Marvin M. van Luijn
Objective To study whether glucocorticoid (GC) resistance delineates disease-relevant T helper (Th) subsets that home to the CNS of patients with early MS. Methods The expression of key determinants of GC sensitivity, multidrug resistance protein 1 (MDR1/ABCB1) and glucocorticoid receptor (GR/NR3C1), was investigated in proinflammatory Th subsets and compared between natalizumab-treated patients with MS and healthy individuals. Blood, CSF, and brain compartments from patients with MS were assessed for the recruitment of GC-resistant Th subsets using fluorescence-activated cell sorting (FACS), quantitative polymerase chain reaction (qPCR), immunohistochemistry, and immunofluorescence. Results An MS-associated Th subset termed Th17.1 showed a distinct GC-resistant phenotype as reflected by high MDR1 and low GR expression. This expression ratio was further elevated in Th17.1 cells that accumulated in the blood of patients with MS treated with natalizumab, a drug that prevents their entry into the CNS. Proinflammatory markers C-C chemokine receptor 6, IL-23R, IFN-γ, and GM-CSF were increased in MDR1-expressing Th17.1 cells. This subset predominated the CSF of patients with early MS, which was not seen in the paired blood or in the CSF from patients with other inflammatory and noninflammatory neurologic disorders. The potential of MDR1-expressing Th17.1 cells to infiltrate brain tissue was confirmed by their presence in MS white matter lesions. Conclusion This study reveals that GC resistance coincides with preferential CNS recruitment of pathogenic Th17.1 cells, which may hamper the long-term efficacy of GCs in early MS.

13 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
Steven C. KoetzierSteven C. Koetzier
Steven C. Koetzier
JLJamie Van Langelaar
Jamie Van Langelaar
MMMarie-José Melief
Marie-José Melief
AWAnnet F. Wierenga-Wolf
Annet F. Wierenga-Wolf
CCCato E. A. Corsten
Cato E. A. Corsten
JSJoost Smolders
Joost Smolders
The effector programs of CD8+ memory T cells are influenced by the transcription factors RUNX3, EOMES and T-bet. How these factors define brain-homing CD8+ memory T cells in multiple sclerosis (MS) remains unknown. To address this, we analyzed blood, CSF and brain tissues from MS patients for the impact of differential RUNX3, EOMES and T-bet expression on CD8+ T cell effector phenotypes. The frequencies of RUNX3- and EOMES-, but not T-bet-expressing CD8+ memory T cells were reduced in the blood of treatment-naïve MS patients as compared to healthy controls. Such reductions were not seen in MS patients treated with natalizumab (anti-VLA-4 Ab). We found an additional loss of T-bet in RUNX3-expressing cells, which was associated with the presence of MS risk SNP rs6672420 (RUNX3). RUNX3+EOMES+T-bet− CD8+ memory T cells were enriched for the brain residency-associated markers CCR5, granzyme K, CD20 and CD69 and selectively dominated the MS CSF. In MS brain tissues, T-bet coexpression was recovered in CD20dim and CD69+ CD8+ T cells, and was accompanied by increased coproduction of granzyme K and B. These results indicate that coexpression of RUNX3 and EOMES, but not T-bet, defines CD8+ memory T cells with a pre-existing brain residency-associated phenotype such that they are prone to enter the CNS in MS.

5 February 2025 in European Journal of Neurology
Verified
Journal Article
Open access
KBKatelijn M. Blok
Katelijn M. Blok
RKRomy A. M. Klein Kranenbarg
Romy A. M. Klein Kranenbarg
KAKirtana Ananth
Kirtana Ananth
HEHendrik J. Engelenburg
Hendrik J. Engelenburg
ABAletta van Den Bosch
Aletta van Den Bosch
JSJoost Smolders
Joost Smolders
Background: Relapsing–remitting (RR) and primary progressive (PP) multiple sclerosis (MS) have distinct clinical courses, but underlying pathophysiological differences remain unclear. We compared pathological components between RRMS, PPMS, and other inflammatory and neurodegenerative disorders, leveraging soluble biomarkers and post‐mortem pathology.Methods: Serum and cerebrospinal fluid (CSF) of people diagnosed with (pw) PPMS (n = 104), RRMS (n = 38), Alzheimer's disease (AD, n = 22), neuromyelitis optica spectrum disorder (NMOSD, n = 10), and myelin oligodendrocyte glycoprotein–associated disease (MOGAD, n = 10) were collected. B‐cell maturation antigen (BCMA), soluble CD27 (sCD27), osteopontin (OPN), chitinase‐3‐like‐1 (CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and synaptosomal‐associated protein‐25 (SNAP25) were measured. Lymphocytes (CD20+, CD138+, CD3+) and pyramidal‐tract axonal density in RR‐onset (n = 86) and PPMS (n = 45) post‐mortem brain tissue were quantified.Results: Soluble and post‐mortem tissue biomarkers did not differ between pwRRMS and pwPPMS. Compared to AD, MS had higher CSF sCD27 (p < 0.001) but lower serum CHI3L1 and GFAP, and CSF OPN and SNAP25 (all p < 0.05). Serum OPN was lower in RRMS than NMOSD (p = 0.013). Principal component analyses and K‐means clustering showed substantial overlap of RRMS and PPMS biomarkers, distinct from AD. In all pwMS, serum NfL and CSF BCMA correlated with clinical/radiological disease activity, CSF BCMA and sCD27 with inflammatory parameters, and serum GFAP, CSF GFAP, and CSF NfL with Expanded Disability Status Scale (EDSS) score.Conclusions: Serum and CSF soluble biomarker profiles and post‐mortem pathology do not differentiate RRMS from PPMS diagnoses but reflect the extent of inflammation and tissue damage. Detailed assessment of MS‐associated inflammation and tissue damage may enhance classification and therapeutic strategies.

15 September 2023 in European Journal of Neurology
Verified
Journal Article
Open access
KBKatelijn M. Blok
Katelijn M. Blok
JSJoost Smolders
Joost Smolders
JRJoost van Rosmalen
Joost van Rosmalen
CJCarine O. Martins Jarnalo
Carine O. Martins Jarnalo
BWBeatrijs Wokke
Beatrijs Wokke
JBJanet de Beukelaar
Janet de Beukelaar
Background and purpose: Despite the 2017 revisions to the McDonald criteria, diagnosing primary progressive multiple sclerosis (PPMS) remains challenging. To improve clinical practice, the aim was to identify frequent diagnostic challenges in a real‐world setting and associate these with the performance of the 2010 and 2017 PPMS diagnostic McDonald criteria.Methods: Clinical, radiological and laboratory characteristics at the time of diagnosis were retrospectively recorded from designated PPMS patient files. Possible complicating factors were recorded such as confounding comorbidity, signs indicative of alternative diagnoses, possible earlier relapses and/or incomplete diagnostic work‐up (no cerebrospinal fluid examination and/or magnetic resonance imaging brain and spinal cord). The percentages of patients fulfilling the 2010 and 2017 McDonald criteria were calculated after censoring patients with these complicating factors.Results: A total of 322 designated PPMS patients were included. Of all participants, it was found that n = 28/322 had confounding comorbidity and/or signs indicative of alternative diagnoses, n = 103/294 had possible initial relapsing and/or uncertainly progressive phenotypes and n = 73/191 received an incomplete diagnostic work‐up. When applying the 2010 and 2017 diagnostic PPMS McDonald criteria on n = 118 cases with a full diagnostic work‐up and a primary progressive disease course without a better alternative explanation, these were met by 104/118 (88.1%) and 98/118 remaining patients (83.1%), respectively (p = 0.15).Conclusion: Accurate interpretation of the initial clinical course, consideration of alternative diagnoses and a full diagnostic work‐up are the cornerstones of a PPMS diagnosis. When these conditions are met, the 2010 and 2017 McDonald criteria for PPMS perform similarly, emphasizing the importance of their appropriate application in clinical practice.